Results 41 to 50 of about 56,596 (269)
The purpose of this study was to evaluate the effect of 8 months of treatment with itraconazole on airway wall thickness in patients with severe persistent asthma.
Farnaz Aligolighasemabadi +6 more
doaj +1 more source
Effect of itraconazole on the cornea in a murine suture model and penetrating keratoplasty model [PDF]
AIM: To investigate the anti-(lymph)angiogenic and/or anti-inflammatory effect of itraconazole in a corneal suture model and penetrating keratoplasty (PK) model.
Yang Kyung Cho +3 more
doaj +1 more source
Blood and Lung Concentrations of Itraconazole and its Active Metabolite in Patients with Pulmonary Aspergillosis [PDF]
application/pdfAN0016561X-20190930-127A patient was given generic itraconazole (ITCZ) tablet, brand-name-ITCZ capsule, ITCZ oral solution and ITCZ injection to treat pulmonary aspergillosis.
仲村, 弥栄子 +26 more
core +1 more source
Plasma concentrations of itraconazole and hydroxy-itraconazole following oral administration of 200 mg itraconazole once daily or reference itraconazole (PK analysis set).
M. Bhrushundi (14614849) +11 more
core +1 more source
CAQ Corner: Basic concepts of transplant immunology
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Blood concentrations of itraconazole and metabolite after oral administration to a patient with partial gastrectomy : A comparison between solid preparation and oral solution [PDF]
application/pdfAN0016561X-20200316-137In this paper, we report that in pulmonary aspergillosis patient who had history of resection of the stomach, the blood concentrations of itraconazole(ITCZ)and its active metabolite, hydroxy-ITCZ(OHITCZ) after taking
6010 +21 more
core +1 more source
BackgroundChronic pulmonary aspergillosis (CPA) requires prolonged treatment with itraconazole or voriconazole. However, adverse events (AEs) are common with the use of these agents, with the need to discontinue the offending drug in a significant ...
Ronald Olum +4 more
doaj +1 more source
Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
Gilteritinib, an FDA-approved tyrosine kinase inhibitor approved for the treatment of relapsed/refractory FLT3-mutated acute myeloid leukemia, is primarily eliminated via CYP3A4-mediated metabolism, a pathway that is sensitive to the co-administration of
Dominique A. Garrison +6 more
doaj +1 more source
Antimicrobial susceptibility testing of dermatophytes - Comparison of the agar macrodilution and broth microdilution tests [PDF]
Fifty dermatophyte strains, recently obtained from clinical material, belonging to 4 different species were examined for their susceptibility to 5 systemic or topical antimycotic agents using both an agar macrodilution and a broth microdilution test ...
Korting, Hans Christian +5 more
core +1 more source
In vitro activity of itraconazole against SARS‐CoV‐2
Background As long as there is no vaccine available, having access to inhibitors of SARS-CoV-2 will be of utmost importance. Antivirals against coronaviruses do not exist, hence global drug re-purposing efforts have been carried out to identify agents ...
E. Van Damme +10 more
semanticscholar +1 more source

